Latest TNF inhibitor Stories
-- Hungarian National Registry reports interim results following Inflectra therapy in 90 patients with Crohn's disease and ulcerative colitis BARCELONA and MADRID, Spain, Feb.
-- Major European markets can finally benefit from the availability of Inflectra following the patent expiry of reference product Remicade® (infliximab) LAKE FOREST, Ill., Feb.
CRANBURY, N.J., Feb.
FIRST OF SEVERAL PHASE 3 TRIALS TO REPORT RESULTS INDIANAPOLIS, Dec.
Sales of Biologics Will Contribute Approximately $2.3 Billion to the UC Market in 2023, According to Findings from Decision Resources Group BURLINGTON, Mass., Nov.
Presentations examine certain demographic and clinical disease characteristics that may be indicative of Cimzia® treatment response and remission for moderate to severe Crohn's disease ATLANTA,
AG014 Safe and Well Tolerated, Successful Localized GI Delivery of Drug With No Systemic Exposure GHENT, Belgium, Oct.
Patient Shares For Newer Alternative MOA Agents Are Also Expected To Grow In The Next Six Months, According To Findings From Decision Resources Group BURLINGTON, Mass., Oct.
-- Polyarticular juvenile idiopathic arthritis (JIA) occurs in approximately 25 percent of all JIA patients NORTH CHICAGO, Ill., Oct.
-- HUMIRA is now indicated to treat pediatric patients 6 years of age and older with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators
- In medieval musical notation, a sign or neume denoting a shake or trill.